Conflict of interest
Sarah Ahn
ONCOLOGY
Antoinette R. Tan reports institutional clinical trial support and personal fees from G1 Therapeutics, Inc.; outside of the submitted work, institutional clinical trial support from Arvinas, Genentech/Roche, Merck, and Pfizer, and personal fees from AstraZeneca, Genentech/Roche, Jazz Pharmaceuticals, Novartis, Puma, Seagen, and Stemline Therapeutics. Joyce O’Shaughnessy reports institutional clinical trial support and personal fees from G1 Therapeutics, Inc.; outside of the submitted work, personal fees from AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BMS, Celgene, Eisai, Genentech, Immunomedics, Ipsen, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, Prime Oncology, Puma Biotechnology, Roche, Seattle Genetics, and Syndax Pharmaceuticals. Subing Cao and Sarah Ahn (at the time of the study), and John S. Yi are paid employees and shareowners of G1 Therapeutics, Inc.